NCT06715540 - Safety, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Ascending Doses BCD-261 in Healthy Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 29, 2024

Primary Completion Date

February 28, 2025

Study Completion Date

December 31, 2025

Conditions

Healthy

Interventions

DRUG

BCD-261, dose 1

Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials

DRUG

BCD-261, dose 2

Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials

DRUG

BCD-261, dose 3

Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials

DRUG

BCD-261, dose 4

Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials

DRUG

BCD-261, dose 5

Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials

DRUG

BCD-261, dose 6

Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials

DRUG

BCD-261, pre-specified therapeautic dose X

Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in vials

DRUG

BCD-261, pre-specified therapeautic dose X

Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in pre-filled syringes

DRUG

BCD-261, pre-specified therapeautic dose Y

Anti-TL1A human monoclonal antibody. Solution for Subcutaneous Injection in pre-filled syringes

Trial Locations (1)

RECRUITING

"Meditsinskiy teсhnologiy Maly", Saint Petersburg